We investigated the effects of estradiol on bioactive luteinizing hormone (LH) release in normal men using two complementary strategies: (i) steady state intravenous infusions of estradiol at its endogenous production rate, and (ii) oral administration of the antiestrogen, tamoxifen HC. Immunoreactive and biologically active LH were monitored by radioimmunoassay and the rat interstitial cell testosterone bioassay, respectively. Estradiol infusions significantly suppressed mean plasma bioactive LH concentrations and decreased the bio/ immuno LH ratio. Conversely, antiestrogen treatment enhanced spontaneous bioactive LH pulse frequency, increased bioactive LH pulse amplitude, and augmented plasma intrapulse and interpulse bio/immuno LH ratios. Low-dose pulsed injections of exogenous gonadotropin-releasing hormone (GnRHI) also increased plasma bio/immuno LH ratios. However, tamoxifen attenuated the ability of exogenous GnRH to further enhance the bio/immuno LH ratio, which suggests that endogenous LH release was already maximally enriched in LH bioactivity during antiestrogen administration.
Introduction
Studies in experimental animals have suggested that sex steroid hormones may modulate the pituitary secretion of not only immunoactive gonadotropins but also biologically active hormones (1) (2) (3) (4) . In the rat, castration results in a disproportionate increase in the circulating concentrations of immunoreactive luteinizing hormone (LH)' as compared with biologically active LH (5) . This relative decrease in the bio/immuno LH ratio is attenuated by testosterone and 5a-dihydrotestosterone replacement. However, in the human, menopause and/or gonadal failure result in preferentially increased bioactive LH concentrations with high plasma bio/immuno LH 1. Abbreviations used in this paper: GnRH, gonadotropin-releasing hormone; LH, luteinizing hormone; RICT, rat interstitial cell testosterone.
ratios (6) . The high level of bioactive LH in primary ovarian failure can be suppressed by oral administration of estrogen (7) . The latter observation is consistent with the demonstration that young women of reproductive age who have high endogenous estradiol levels exhibit significantly lower plasma bio/immuno LH ratios than postmenopausal women or young men (8) . The latter disparity between young women and men might reflect either a putative suppressive effect ofestradiol on bioactive LH secretion in women, or a facilitative effect of testosterone on bioactive LH release in men. Accordingly, the exact nature of the effects of endogenous sex steroids on the bioactivity of circulating LH cannot be readily ascertained. Moreover, presumptive actions ofsex steroids on physiological patterns of pulsatile bioactive LH release have not been defined.
In the present work, we have employed two complementary strategies to examine the role of estradiol in modulating the secretion of biologically active LH in the human. First, we investigated bioactive LH release in men subjected to steady state estradiol infusions. Secondly, we administered tamoxifen hydrochloride, a pharmacological antagonist of estrogen action (9) , to appraise the feedback actions of endogenous estradiol on spontaneous and exogenous gonadotropin-releasing hormone (GnRH)-stimulated pulsatile bioactive LH release. We used the rat interstitial cell testosterone (RICT) bioassay to estimate the quantity of biologically active LH in plasma under these conditions of experimentally perturbed estrogen action.
Methods
Patient characteristics 21 normal men (ages [21] [22] [23] [24] [25] [26] [27] [28] [29] participated in this study after provision of written informed consent, which was approved by the Human Investigation Committee of the University of Virginia School of Medicine. Each individual had normal serum concentrations ofimmunoreactive cortisol, thyroxine, prolactin, LH, follicle-stimulating hormone, thyroid-stimulating hormone, equilibrium-dialyzable plasma free testosterone (10), and estradiol (10), and had normal hepatic, renal, and hematological function.
Clinical protocols
Estradiol infusion. Chromatographically pure estradiol (assessed by high-pressure liquid chromatography) was dissolved in sterile ethanol, which was diluted in 5% dextrose in water immediately before infusions. I liter of 5% dextrose in water containing 48 ,ug 1 8 .4% (at 2 mIU/ml), 6 .8% (at 11.5 mIU/ml), and 4.6% (at 47 mIU/ml) for the RIA, which exhibits < 15% crossreactivity with alpha subunit. The intraassay coefficient of variation for the bioassay averaged 8.5% with a range of 8.2-9.2% in children and postmenopausal women.
Pulse analysis
To minimize assumptions regarding the shape, frequency, amplitude, or baseline stability of the bioactive LH time-concentration profiles under control or treated conditions, we applied a simple statistical algorithm previously validated for the detection ofsignificant increases or decreases in data series of known variance (12) . This method, termed "Cluster" analysis, evaluates successive clusters of designated sizes in relation to an indicated t statistic, marks all significant increases and decreases in the data series, and then designates a peak as a region comprising an increase followed by a decrease. The choice of t statistics permits one to designate an estimated maximal false-positive rate for peak detection assuming Gaussian-distributed measurement error (12) . Regions in the data that contain no significant increases or decreases are identified as interpulse "valleys." In the present analyses, the t statistic was selected to maintain a maximal false-positive rate of 1% by using test cluster sizes of two in the prepeak nadir, peak, and postpeak nadir.
The results of Cluster analysis permit one to quantitate the following properties of pulsatile hormone release: (a) number of statistically significant peaks (pulse frequency); (b) the mean interval between peaks (interpulse interval in min); (c) the mean peak width (duration in min); (d) the maximal peak height (mIU/ml); (e) the maximal peak height expressed as a percent increase above nadir (fractional amplitude); (f) the peak height expressed as an increment (mIU/ml) above preceding nadir, (g) the number of valleys (regions without any significant increase or decrease in the data); (h) average valley duration (min); and (i) average valley mean LH concentration (mIU/ml) (12) . We used the method ofSanten and Bardin (13) to determine integrated LH concentrations over the 12-h baseline sampling.
Statistical analysis
Within-subject differences were sought by paired two-tailed Student's t testing when mean plasma hormone concentrations were compared.
Because of departures from normality, individual pulse parameters were compared using the Wilcoxon ranked sign test (14) . Plasma bio/ immuno LH ratios were compared by parametric methods after logarithmic transformation. Results are expressed as means±SEM or median values. Statistical significance was construed for P . 0.05.
Results

Steady state infusion ofestradiol
As shown in Fig. 1 A, during steady state infusion of estradiol mean plasma concentrations of immunoactive and bioactive LH declined significantly (P = 0.013 and P = 0.0 16, respectively). This infusion regimen resulted in an increase in mean serum estradiol concentrations from 32±4 pg/ml basally to 64±5 pg/ml over the last 8 h of the infusion (P < 0.01). Since we have previously shown that equilibrium is achieved within 24 h (10), this paradigm permitted us to appraise the influence of steady state plasma estradiol elevations on the bio/immuno LH ratio. In response to estradiol infusion, there was a more pronounced decline in circulating bioactive than immunoactive LH concentrations, which was reflected in a significant decline in plasma bio/immuno LH ratios in these seven men (P = 0.0097 Fig. 1 B) . These measurements of LH bioactivity and immunoactivity were derived from a pool of aliquots of plasma removed from samples collected at 4-min intervals over 8 h, and as such provide an accurate estimate of integrated plasma LH concentrations over this interval. antiestrogen administration. The mean plasma immunoactive LH concentration also increased, although the fractional increase above baseline was of lesser magnitude; namely, basal 15.0±0.78 mIU/ml to 21.4±1.4 mIU/ml after 10 d of tamoxifen. Accordingly, the median bio/immuno LH ratios in these men increased significantly, i.e., from 2.1 basally to 3.1 and 3.0 after, respectively, 3 and 10 d of antiestrogen (P = 0.019). Under these conditions, total serum testosterone concentrations also increased significantly (Fig. 2 B) .
Impact ofantagonism ofendogenous estrogen action on 12-h mean concentrations and the pulsatile release of biologically active LH Mean and integrated plasma LH concentrations. Based upon the preceding dose-and time-course studies, we studied the effects of endogenous estradiol on the pulsatile release of bioactive LH by sampling blood at 10-min intervals for 16 h under basal conditions, and again after the administration of tamoxifen for 7 d. During the last 4 h of sampling, two pulses ofGnRH (10 ,ug) were infused intravenously at 2-h intervals to test pituitary responsiveness. The 1st 12 h of sampling was used to evaluate the impact ofantiestrogen treatment on spontaneous (endogenous GnRH driven) release of bioactive LH.
As shown in Fig. 3 A, the 12-h mean and integrated plasma concentrations of bioactive LH increased significantly (P = 0.033 and P = 0.034, respectively) in response to tamoxifen administration. In contrast, this lower dose of tamoxifen (10 mg every 12 h) elicited no significant increase in mean or integrated serum concentrations of immunoactive LH (P = 0.68 and P = 0.66, respectively). Moreover, under these conditions, total serum testosterone concentrations rose significantly (P = 0.004; Fig. 3 B) , but plasma free testosterone con- I centrations rose only minimally (namely, from 96.4±1 1 pg/ml to 128±22 pg/ml, P = 0.19). This pattern reflected a slight decrease in the percent dialyzable (free) testosterone in plasma after tamoxifen treatment (percent dialyzable testosterone declined from 1.94±0.13 to 1.83±0.14; P = 0.23). Mean plasma estradiol concentrations were unchanged, i.e., basal levels were. 23.7+3.0 pg/ml as compared with 24.2±3.7 pg/ml after tamoxifen treatment (P = 0.85). Accordingly, the present schedule of antiestrogen administration permitted us to examine changes in plasma bioactive LH release in the absence of any major perturbations in serum concentrations of immunoactive LH, free testosterone, or estradiol.
Effects of antiestrogen on specific properties ofpulsatile bioactive LH release. The plasma collected at 10-min intervals for 12 h under basal and tamoxifen-treated conditions allowed us to assess the effect of antiestrogen on specific properties of pulsatile bioactive LH release. Using the validated Cluster analysis method adjusted to an estimated maximal false-positive rate of 1%, we observed that bioactive LH pulse frequency (number of pulses counted per 12 h) increased significantly in conjunction with antiestrogen administration; namely, from 5.3±0.33 pulses/12 h (median 5.5) basally to 7.5±0.22 pulses/ 12 h (median 7.5) after tamoxifen (P = 0.029; Fig. 4 A) .2 Correspondingly, the basal bioactive LH interpulse interval of 113±7.9 min (median 105) declined to 85±2.6 min (median 84) in association with antiestrogen treatment (P = 0.029 by nonparametric testing; Fig. 4 B) .
Administration of a dose of antiestrogen sufficient to increase mean and integrated plasma concentrations ofbioactive LH also elicited significant and distinct changes in LH pulse properties. As shown in Fig. 5 , the duration of bioactive LH peaks decreased significantly from a median value of 99 to 71 min during tamoxifen administration (P = 0.029). This occurred in association with a significant increase in absolute (maximal) amplitude of the bioactive LH peak, which rose from a median value of 50 to 65 mIU/ml (P = 0.029). Thus, tamoxifen had reciprocal effects on peak width (which decreased) and a maximal peak height (which increased). This interaction resulted in no significant changes in mean bioactive LH peak area (milliinternational units per milliliter times minute), which was 1,000±130 (basal) and 900±180 (after tamoxifen) (P = 0.46).
Mean interpulse valley (region of nonpulsatility) bioactive LH concentrations also increased significantly during tamoxifen administration, namely, from 32±5.4 to 49±11 mIU/ml (P = 0.02 over basal); whereas, incremental LH pulse amplitudes did not change significantly ( Fig. 5 ; median basal 18 mIU/ml and posttamoxifen 23 mIU/ml). Also, the duration (minutes) of the interpulse valleys was not altered significantly by antiestrogen: interpulse valley durations of 30±4 min (basal) vs. 31±0.68 min (posttamoxifen) (P = 0.079).
Profiles ofbio-and immunoactive LH release in control and antiestrogen treatment sessions Individual profiles of bio-and immunoactive LH release are shown in Fig. 6 , in which control and tamoxifen treatment 2. LH pulse frequency per se may overestimate the interpulse interval because of regions of nonpulsatility at the begining and end of the sampling interval. This "edge" artifact does not occur for measured interpulse intervals. Fig. 7 (top), mean baseline (pre-GnRH) plasma bioactive LH concentrations were increased significantly in the tamoxifen-treated group (P = 0.023 and P = 0.001, respectively, for the first and second baseline hours). In response to the first and second injections of GnRH, mean plasma bioactive LH concentrations increased significantly in both the control and tamoxifen-treated sessions (P < 0.001). However, the degree of increase in plasma bioactive LH concentrations in response to two consecutive exogenous GnRH pulses was significantly reduced in the tamoxifen treatment session as compared with control (P 0100 1000 1200 1400 1600 1800 2000 220 2400 0100 1000 1200 1400 1600 1800 2000 220 2400 TIME (hours) TIME (hours) < 0.004 to P < 0.014 for hours [3] [4] [5] [6] . A similar pattern of relatively suppressed LH responses to GnRH after tamoxifen administration was observed for immunoactive LH (Fig. 7,  middle) . We noted that for both immuno-and bioactive LH, tamoxifen treatment resulted in greater suppression of the GnRH. maximal response to the first rather than second pulse of GnRH (P < 0.02).
Under basal conditions (no tamoxifen), hourly median plasma bio/immuno LH ratios increased significantly in response to exogenous pulses of GnRH (P < 0.001) (Fig. 7, bot tom). When antiestrogen was administered, baseline (preGnRH) median bio/immuno LH ratios increased significantly above control levels (hours 1 and 2, P = 0.003). However, stimulation with two consecutive pulses of GnRH did not result in any further increase in the plasma bio/immuno LH ratio during tamoxifen treatment. Rather, the median plasma bio/immuno LH ratios were significantly reduced 2 h after the second GnRH pulse (hour 4, P = 0.036).
Analysis ofthe impact of antiestrogen administration on intra-and interpulse plasma bio/immuno LH ratios in men
In both control and tamoxifen treatment sessions, the plasma bio/immuno LH ratios were significantly higher within spontaneous pulses than in the corresponding interpulse intervals (P = 0.01 in the control session, and P = 0.008 in the tamoxifen treatment session; Fig. 8 ). Tamoxifen treatment resulted in a significant increase in both spontaneous inter-and intrapulse bio/immuno LH ratios (P = 0.008 and P = 0.003, respectively). In contrast, antiestrogen administration attenuated the ability of exogenous GnRH to increase the bio/immuno LH ratio further, which suggests the attainment of maximal enrichment in endogenous LH bioactivity in the presence of antiestrogen.
* Control Figure 8 . (17) and in some, but not all cases to increase immunoactive LH pulsatility in vivo (18) (19) (20) Although endogenous LH production rates have not yet been measured in response to estrogen infusion or antiestrogen administration in man, the present results would be consistent with a suppressive effect ofestradiol infusion and a stimulatory effect of antiestrogen administration on endogenous LH production. Moreover, endogenous estrogen excess has been reported to profoundly suppress bioactive LH release (27) . Accordingly, the changes we observed in plasma bio/immuno LH ratios might reflect a property of pituitary gonadotropes to secrete LH molecules relatively enriched in bioactivity whenever production rates are increased and to secrete LH molecules relatively impoverished in biological activity whenever LH secretion rates are suppressed. This hypothesis would accord with the striking rise in circulating LH bioactivity observed in castrate or postmenopausal individuals, in whom LH production rates are increased (7) . However, this interpretation would not account for the recent observation that nonsteroidal suppression of endogenous LH secretion with a potent and selective GnRH antagonist results in a parallel decline in plasma bio-and immunoactive LH concentrations with no discernible variation in the plasma bio/immuno LH ratio over time (28) . Alternatively, estrogen or antiestrogen might affect the metabolic clearance of LH. However, available data suggest that sex steroid hormones do not have a major influence on gonadotropin clearance in man (29, 30) . Moreover, alterations in metabolic clearance would not account for enhanced bioactive LH pulse frequency and attenuated GnRH-stimulated LH release in the presence oftamoxifen. Accordingly, we infer that estradiol modulates the secretion of bioactive LH by mechanisms that are not dependent upon altered hormone secretion or clearance rates per se.
In summary, we have utilized two complementary strategies to appraise the influence of estradiol on the secretion of biologically active LH in man. Our results with steady state estradiol infusion and a selective antiestrogen indicate that endogenous estradiol modulates the pulsatile secretion of LH molecules enriched in biological activity. Such observations suggest a critical role for estradiol in regulating the functional attributes of the pituitary-gonadal axis in man.
